# Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

> **NCT05608785** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal-junction Cancer

## Interventions

- **DRUG:** IBI315
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** TST001
- **DRUG:** TQB2450
- **DRUG:** Anrotinib

## Key facts

- **NCT ID:** NCT05608785
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-10-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05608785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05608785, "Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05608785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*